Frailty, Not Age, Drives Risks With SGLT2, GLP-1 Drugs in Older Adults
Cardiometabolic drugs such as SGLT2 inhibitors and GLP-1 receptor agonists offer substantial benefits for older adults, but clinicians should base prescribing decisions on a patient’s frailty and comorbidities rather than age alone, experts said at the American Geriatrics Society (AGS) 2026 Annual Scientific Meeting.
SGLT2 inhibitors are linked to side effects such as genital infections, dehydration, and dizziness, which may increase the risk for falls in older adults. GLP-1 drugs often cause nausea and weight loss, which may be harmful in patients already at risk for frailty or muscle loss.
“The key thing is that risk is vulnerability dependent, not age dependent,” said Chintan Dave, PhD, associate professor of pharmacy and epidemiology at Rutgers University School of Public Health in New Brunswick, New Jersey.
Rats, that’s why the title didn’t come up in search. That was before I joined the site in August of that year. I should have known, no way would you miss an RCT involving dapa and dementia. The study is small, and short duration, but still somewhat interesting.
Just want to confirm that I was able to get a 3 month supply of Dapagliflozin, 10mg for a total of $30 with express shipping. Would have been $15 with regular shipping.
